The short answer
Danuglipron, or PF-06882961, was Pfizer's oral small-molecule GLP-1 receptor agonist for chronic weight management. Development was discontinued in April 2025 after a single asymptomatic participant experienced potential drug-induced liver injury, which resolved after the drug was stopped.
Key facts
- Development code
- PF-06882961
- Developer
- Pfizer
- Class
- Oral small-molecule GLP-1 receptor agonist
- Phase 2b published
- Diabetes Obes Metab 2025 (PMID 40539310)
- Discontinued
- April 2025
- Trigger
- One asymptomatic DILI case, resolved on stopping
- Safety database
- Over 1,400 participants
- Enzyme elevations overall
- In line with approved agents in the class
What it was
A non-peptide GLP-1 receptor agonist small enough to survive the digestive tract and be absorbed as an ordinary tablet, the same basic proposition as orforglipron and aleniglipron. Its Phase 2b results in adults with obesity were published in Diabetes, Obesity and Metabolism in September 2025, after the programme had already been stopped.
Why the discontinuation is more interesting than it looks
The dose-optimisation studies had met their key pharmacokinetic objectives. Pfizer's own update stated that across a safety database of more than 1,400 participants, the frequency of liver enzyme elevations was in line with approved agents in the class. So the programme was not stopped because danuglipron looked worse than the drugs already on the market.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What actually ended it
One participant. A single asymptomatic case of potential drug-induced liver injury in a dose-optimisation study, which resolved after the drug was discontinued. Pfizer described the decision as following a review of the totality of information including regulator input, and concluded the risk-benefit profile did not support continuing.
Why one case can be decisive
Because of what obesity medicine is. A drug for a chronic condition, taken by very large numbers of people for years, with several effective alternatives already licensed, has almost no tolerance for a serious idiosyncratic risk. The same single case in a compound treating a condition with no alternatives would be weighed completely differently. Risk-benefit is a ratio, and the denominator here was crowded.
What it changed for everything that followed
It made hepatic safety the question every subsequent oral small molecule had to answer first. When the aleniglipron Phase 2b appeared in Nature Medicine in August 2026, the sentence that mattered to the field was not the 12.1% weight reduction. It was that no cases of drug-induced liver injury occurred. Most coverage led with the weight number.
What this does not concern
Research material of any kind. Danuglipron was an investigational medicine in registered clinical trials under clinical supervision, it was never licensed, and its development has ceased. Nothing supplied here is related to it or to any other GLP-1 receptor agonist.
Frequently asked questions
Why was danuglipron discontinued?
A single asymptomatic participant experienced potential drug-induced liver injury, which resolved after stopping. Pfizer concluded the risk-benefit profile did not support further development.
Were its liver signals worse than other GLP-1 drugs?
No. Pfizer stated that across over 1,400 participants, liver enzyme elevation frequency was in line with approved agents in the class.
Did the drug fail on efficacy?
No. The dose-optimisation studies met their key pharmacokinetic objectives before the programme was stopped.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBuckeridge C et al., Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a phase 2b study. Diabetes Obes Metab 2025 (PMID 40539310)pubmed.ncbi.nlm.nih.gov
- RefPfizer: update on oral GLP-1 receptor agonist danuglipronpfizer.com
- PubMedRosenstock J et al., Oral small molecule GLP-1 receptor agonist aleniglipron: phase 2b. Nat Med 2026 (PMID 42249138)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Hepatic Safety Became the Oral GLP-1 QuestionInjectable peptide GLP-1s did not raise this question. Small molecules do, because of how they are metabolised - and one programme has already ended over it.
- Hy's Law: How Trials Decide a Drug Hurt the LiverThree measurements and an exclusion. What Hy's Law is, why it predicts severe outcomes, and why raised enzymes alone mean very little.
- The Obesity Drug That Is Not an IncretinSetmelanotide targets the melanocortin-4 receptor, not GLP-1. An approved medicine for rare genetic obesity, and a different mechanism entirely.
- The Survodutide Comparison, Read ProperlyAn open-label semaglutide arm in a type 2 diabetes dose-finding trial. Why that is weaker evidence than a head-to-head, and what the numbers mean.
- Failing to Show Non-Inferiority Is Not Showing InferiorityREDEFINE 4 missed its non-inferiority endpoint. That is a specific statistical statement, and it is not the same as the drug being worse.